Recent articles

The common belief for decades was that diligent monitoring of blood sugars and intensive insulin therapy had little consequence for people with diabetes. Then the Diabetes Control and Complications Trial (DCCT) took place. This trial, from 1983-1993, would find out if intensive insulin control warded off complications from the disease. (Hint: it does.) A lot […]

In the words of Colin Dayan, M.D., Ph.D., professor of clinical diabetes and metabolism at Cardiff University: “Type 1 diabetes is almost the only major autoimmune disease now that does not have a licensed immunotherapy.” And he’s going to change that.

A clinical trial at four pediatric diabetes centers in the United States has found that a new artificial pancreas system—which automatically monitors and regulates blood-sugar levels—is safe and effective in children as young as age six with type 1 diabetes (T1D): Tandem’s t:slim X2™ insulin pump with Control-IQ™ technology. The algorithm in the Control-IQ technology […]

At the American Diabetes Association’s Scientific Sessions, which was held virtually from June 12-16, scientists presented on some of the most important topics, from artificial pancreas trials to immune therapy trials to prevention trials, all with the same goal: ending type 1 diabetes (T1D) and improving lives until that day comes. Breakthrough T1D played the […]

Low blood sugar, called hypoglycemia, is a real fear for people with type 1 diabetes (T1D). Although there are rescue treatments for it, there are no preventive therapies. Zucara Therapeutics, however, may have an answer. It is developing a once-daily therapy that restores glucagon. Adding glucagon raises blood-sugar levels, preventing hypoglycemia and the symptoms that […]

Breakthrough T1D is honored to recognize five leading international researchers whose work has and is transforming type 1 diabetes (T1D) science. We also are proud that our funding has helped drive their work forward toward both curing type 1 diabetes and improving the lives of those living with the disease today. The recipient of the […]

Universal screening for type 1 diabetes (T1D) is a priority for Breakthrough T1D, but the cost versus benefits remain unclear. Now, a large-scale population study in Bavaria, Germany, headed by Breakthrough T1D-funded Anette-Gabriele Ziegler, M.D., Ph.D., has a clue. The Fr1da study of nearly 100,000 children suggests that screening for autoantibodies—antibodies that are directed toward your […]

Press releases

Read the latest press releases and statements from Breakthrough T1D.

Get the latest in T1D news updates

Sign up for Insider News to receive breaking news updates from Breakthrough T1D.

  • This field is for validation purposes and should be left unchanged.